News

Ortho-McNeil-Janssen has reported that the FDA has issued a complete response letter regarding its New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development. The NDA was

Tibotec has announced a new treatment option for children living with HIV. Two new lower dose 75mg and 150mg formulations of Prezista (darunavir) twice daily, co-administered with low-dose

The FDA has approved Sabril (vigabatrin) oral solution to treat infantile spasms in children aged 1 month to 2 years. Sabril (vigabatrin) Tablets have been approved for adult

Mach One has entered into a multi-year, sole-source agreement with PanTheryx, to supply proprietary bio-based ingredients for manufacturing a broad-spectrum pediatric diarrhea product. Through a wholly owned subsidiary

Orexo has reported net revenues of SEK29.6m for the second quarter of 2009, compared to SEK56.2m for the same period in 2008. The company has also reported a

Lonza has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of $3.55 per Restricted Voting Share. Patheon expects

Epocal has received US Food and Drug Administration’s (FDA) clearance to market its new glucose test on the epoc Blood Analysis System. Imants Lauks, president and founder of

Takeda Canada has re-acquired the Canadian commercial rights to ACTOS, an oral treatment for type 2 diabetes, from Eli Lilly Canada. Takeda, the discoverer of ACTOS, licensed the

MediciNova and Avigen have entered into a definitive merger agreement pursuant to which MediciNova’s wholly-owned subsidiary will merge with and into Avigen. Reportedly, completion of the transaction will